Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.

International journal of oncology - 1 Sept 2021

Uranowska Karolina, Samadaei Mahzeiar, Kalic Tanja, Pinter Matthias, Breiteneder Heimo, Hafner Christine

Abstract excerpt

The overexpression of chondroitin sulfate proteoglycan 4 (CSPG4) is associated with several tumor types, including malignant melanoma, squamous cell carcinoma, triple‑negative breast carcinoma, oligodendrocytomas or gliomas. Due to its restricted distribution in normal tissues, CSPG4 has been considered a potential target for several antitumor approaches, including monoclonal antibody (mAb) therapies. The aim of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chondroitin Sulfate Proteoglycans

Share to Drug Synergism

Share to Melanoma

Share to Proto-Oncogene Proteins B-raf

Share to Spheroids, Cellular

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 34318902
DOI: 10.3892/ijo.2021.5250
PMCID: PMC8357264

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.PMID 34318902Read ↗

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.Semantic proximity Read ↗

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.Semantic proximity Read ↗

Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal TransitionSemantic proximity Read ↗

Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Exogenous Recombinant N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B; ARSB) Inhibits Progression of B16F10 Cutaneous Melanomas and Modulates Cell SignalingSemantic proximity Read ↗

Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.Semantic proximity Read ↗

Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.Semantic proximity Read ↗

Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas.Semantic proximity Read ↗

An Anti-Glypican-2 Monoclonal Antibody, G<sub>2</sub>Mab-7, for Flow Cytometry, Western Blotting, and ImmunohistochemistrySemantic proximity Read ↗

Effect of an anti-human Co-029/tspan8 mouse monoclonal antibody on tumor growth in a nude mouse modelSemantic proximity Read ↗

Differential roles of gangliosides in malignant properties of melanomasSemantic proximity Read ↗

Novel heparan sulfate mimetic compounds as antitumor agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.